New mRNA treatment clears major hurdle

A personalized mRNA melanoma treatment has succeeded in a Phase 3 trial. Here’s what the breakthrough could mean.

11:17 a.m. Aug. 21, 2026

DUANE CROSS
MCO Publisher•Editor

Sunshine is part of the bargain in Moore County. It falls across hayfields, ballfields, gardens, lake water and back porches. By late August, most of us have had our share.

That same sun carries a risk we do not always think much about. Ultraviolet rays are a major cause of skin cancer, including melanoma, the form responsible for most skin-cancer deaths.

Melanoma is uncommon enough here that federal officials will not even publish a reliable rate for Moore County.

But uncommon is not the same as absent.

And this week, a new treatment from Merck and Moderna cleared its biggest test yet – one that could eventually change what happens after surgery for people with high-risk melanoma.

Moore County's numbers are small – but they are real

The latest federal numbers on new cancer diagnoses run through 2022.

From 2018 through 2022, Moore County averaged three or fewer invasive melanoma cases a year. The National Cancer Institute and Centers for Disease Control and Prevention do not publish the county's exact count or melanoma rate because the numbers are too small.

In a county our size, one or two diagnoses can move a rate all over the map. That is why federal officials will not build one from so few cases.

Across all cancers, the numbers are much larger. Moore County averaged about 38 new cancer diagnoses a year from 2018 through 2022.

For melanoma, the statewide numbers give us a better picture. Tennessee averaged about 1,670 melanoma diagnoses a year during that five-year stretch. The state's age-adjusted rate was 20.3 cases per 100,000 people, compared with 23.1 nationally.

Age raises the risk sharply. Among Tennesseans 65 and older, the melanoma rate climbed to 83.4 per 100,000, with about 920 diagnoses a year in that age group alone.

Then there is another number worth noticing. Nearly one in five Tennessee melanoma cases – 19.1% – were classified as late stage, compared with about one in seven nationally.

That is where this week's news starts to matter.

A treatment built for one patient

On Wednesday, Aug. 19, Merck and Moderna announced that a large Phase 3 trial of an experimental personalized mRNA treatment had succeeded in people with high-risk melanoma.

The study included 1,137 patients with stage IIB, IIC, III or IV melanoma. Their visible cancer had already been completely removed by surgery.

Researchers then compared patients who received Keytruda plus Moderna's experimental treatment, called intismeran autogene, with patients who received Keytruda alone.

The combination did better. Patients who received both treatments went longer without their melanoma returning. They also went longer without the cancer coming back somewhere else in the body.

Researchers call those measures recurrence-free survival and distant metastasis-free survival.

Put plainly: after the cancer had been cut out, the new combination did a better job of keeping it away.

For somebody who has heard the words, “We got it all, but now we have to watch,” that is no small thing.

This is not a vaccine off the shelf

Calling intismeran a “cancer vaccine” makes it sound simpler than it is.

This is not a shot a healthy person would get to prevent melanoma. It is a treatment made for one person after that person already has cancer.

Doctors take a sample of the tumor and study the mutations inside it. Scientists then use that genetic fingerprint to create a custom mRNA treatment carrying instructions tied to that patient's cancer.

The treatment can target up to 34 tumor markers. Think of it as giving the immune system a wanted poster. This is what the bad guy looks like. If you see it again, go after it.

Keytruda works alongside that idea. Cancer can use certain signals to put the brakes on the immune system. Keytruda blocks one of those signals.

The personalized mRNA treatment helps show the immune system what to look for. Keytruda helps give it room to work.

That is the science behind the excitement.

There is still a big blank in the story

The announcement is promising. It is also incomplete.

Merck and Moderna have not yet released the full Phase 3 numbers showing how much better the combination performed. We know the trial met its main goals. We do not yet know the size of the benefit.

An earlier Phase 2 study found the combination reduced the relative risk of recurrence or death by 49% and the risk of distant spread or death by 59% after five years compared with Keytruda alone.

Those numbers belong to the smaller, earlier trial. They should not be pinned to this new Phase 3 study unless the full results show the same thing.

Researchers are also still following patients to answer the biggest question of all: Does the treatment help people live longer?

We do not know that yet. So this is not a cure announcement. It is not FDA approval. And it is not something a Moore County patient can expect a doctor to prescribe next week.

But it is a major step.

Why it matters in Moore County

For years, cancer treatment has often meant finding the drug that works best against a certain kind or stage of cancer.

This approach goes further. The medicine itself is designed around the mutations inside one person's tumor.

If regulators eventually approve it, a future Moore County patient with high-risk melanoma could have the cancer removed, have that tumor analyzed, and then receive a treatment built around the genetic fingerprint of that person's own cancer.

Not long ago, that idea would have sounded far-fetched. This week, it cleared a Phase 3 trial – where promising treatments have to prove themselves in a large group of patients before regulators consider wider use.

None of this new science changes the first rule of melanoma. Finding it early matters. A new spot on the skin, or one that changes in size, shape or color, deserves attention. Doctors often use the ABCDE guide: asymmetry, irregular borders, uneven color, diameter, and a spot that is evolving or changing.

Sun protection matters, too. Shade, protective clothing, hats, sunglasses and sunscreen can cut exposure to harmful ultraviolet rays. Tanning beds add another source of UV exposure.

That advice may sound ordinary beside a treatment built from mRNA and the genetic fingerprint of a tumor. But that is how medicine often works. The headlines come from the laboratory. The first chance to make a difference may still come standing in front of the bathroom mirror.

Moore County's numbers are too small to tell us much about our melanoma rate. They do not tell us melanoma cannot happen here.

And for the Moore County neighbor waiting to learn whether the cancer comes back, a treatment built around the genetic fingerprint of that person's own tumor could someday matter a great deal.